Study progress of ponatinib-induced cardiovascular toxicities
10.3760/cma.j.cn114015-20221010-00927
- VernacularTitle:普纳替尼相关心血管毒性的研究进展
- Author:
Qi QIN
1
;
Liangliang TANG
;
Zhiren ZHANG
Author Information
1. 哈尔滨医科大学附属肿瘤医院药学部，哈尔滨 150081
- Publication Type:Journal Article
- Keywords:
Arterial occlusive diseases;
Cardiovascular diseases;
Drug toxicity;
Tyrosine kinase inhibitors;
Ponatinib
- From:
Adverse Drug Reactions Journal
2023;25(8):491-496
- CountryChina
- Language:Chinese
-
Abstract:
Ponatinib is a multi-target tyrosine kinase inhibitor (TKI) indicated as second-line therapy for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. It is the first BCR-ABL kinase inhibitor that targets ABL-T315I, and is effective for patients who have received multiple treatments or lack sensitivity to first or second-generation TKIs. However, the cardiovascular toxicities of ponatinib are frequent and serious. The common cardiovascular adverse events of ponatinib are arterial occlusive events, hypertension, myocardial infarction, etc. The mechanisms of these events might be related to platelet dysfunction, vascular endothelial dysfunction, and myocardial injury. Once adverse cardiovascular events occur in the treatment of ponatinib, dose reduction and even therapy discontinuation are common measures, which might hinder the tumor therapeutic effect in patients. Intervention measures can be formulated according to the "ABCDE" method to reduce the risk of cardiovascular toxicity of ponatinib.
